Dr. James Helliwell reports

EUPRAXIA PHARMACEUTICALS STRENGTHENS BOARD WITH THREE INDUSTRY LEADERS IN DRUG DEVELOPMENT AND COMMERCIALIZATION

Eupraxia Pharmaceuticals Inc. has appointed Robert Bazemore, Amy Pottand and Dr. Helen Thackray to the board of directors.

"We are delighted for Robert, Amy and Helen to join our board of directors at a pivotal stage for the company," said Dr. James A. Helliwell, chief executive officer of Eupraxia. "Their collective expertise across late-stage drug development, commercial strategy and global product launches will be invaluable as we execute on several key upcoming milestones for EP-104GI and continue to expand our pipeline. Their appointments reflect the commitment of Eupraxia to advancing and expanding our gastroenterology assets in an efficient and effective manner. I also want to thank Paul Geyer and Michael Wilmink for all of the support and contributions they have made to Eupraxia over the last decade as we proved the function and potential of the Diffusphere technology."

Robert Bazemore

Mr. Bazemore has spent his career of 30-plus years on the development and commercialization of novel medicines. From 2015 to 2021, he served as president, chief executive officer and director of Epizyme Inc., developing and launching Tazverik for patients with follicular lymphoma and sarcoma, while building on the company's pipeline of promising epigenetic candidates in oncology. Prior to joining Epizyme, Mr. Bazemore served as chief operating officer of Synageva BioPharma Corp., where he established the company's global commercial and medical organization to support the first product launch, helping lead the broader transition to a sustainable commercial enterprise through the company's acquisition by Alexion Pharmaceuticals Inc. in July, 2015. Prior to Synageva, he held several senior leadership positions at Johnson & Johnson, including president of Janssen Biotech, where he led the successful launches of numerous products and indications, including the U.S. launches of the oncology therapies Zytiga and Ibruvica, and guided the company's worldwide Immunology portfolio strategy. Prior to Johnson & Johnson, he served for over 11 years at Merck & Co. Inc., where he held numerous roles, including supporting the launch of Singulair in the United States. Mr. Bazemore is currently a lead independent director for Nuvation Bio Inc., director for Ardelyx Inc. and director for Akari Therapeutics Inc., and was previously a director for Neon Therapeutics prior to its acquisition by BioNTech and board chairman for Pennsylvania BIO. He earned his BS in biochemistry from the University of Georgia.

Amy Pott

Ms. Pott has served as enGene's global chief commercialization officer since May, 2025. She joined enGene from Astellas Pharma, where she served as senior vice-president (SVP), strategic brand marketing, ophthalmics and rare diseases, from April, 2024, to May, 2025, and as head of commercial, gene therapies, from January, 2021, to April, 2024. Prior to Astellas, she was president, North America, from April, 2019, to October, 2020, at Swedish Orphan Biovitrum. At Shire, she was global vice-president (GVP), U.S. franchise head for internal medicine and oncology, from October, 2017, to March, 2019, and she was GVP, U.S. commercial operations, from July, 2016, to October, 2017. Before joining Shire, Ms. Pott was vice-president, strategy, planning and analytics, at Baxalta Inc. Ms. Pott holds a masters of science in European studies from the London School of Economics and a bachelor of arts in history from the University of Bristol.

Dr. Helen Thackray

Dr. Thackray brings more than 25 years of leadership experience at three biotechnology companies, ranging from preclinical start-up to a mature public company with $2-billion market cap and three approved products. Most recently, she served as the chief research and development officer at BioCryst Pharmaceuticals, where she oversaw research and development (R&D), regulatory affairs, medical affairs, and portfolio strategy. Prior to BioCryst, she held senior leadership positions at GlycoMimetics Inc. from 2006 to 2021, including senior vice-president of clinical development and chief medical officer. In addition, she has served on two public company boards (BioCryst and ImmunoGen), each spanning the period from pivotal trials through commercial transition and initial market launch. She is a board-certified pediatrician, serving on the faculty of the Children's National Medical Center and George Washington University School of Medicine and Health Sciences from 2000 to 2025. Dr. Thackray holds a bachelor of science degree in biological sciences from Stanford University and an MD from George Washington University, and has written more than 60 peer-reviewed articles and presentations. She completed her pediatric residency and chief residency at Children's National Medical Center, trained in medical genetics at the National Human Genome Research Institute at the National Institutes of Health, and is a fellow of the American Academy of Pediatrics (FAAP).

About Eupraxia Pharmaceuticals Inc.

Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Diffusphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The technology is designed to support extended duration of effect and delivery of drugs in a hyperlocalized fashion, targeting only the tissues that physicians are wanting to treat. The company believes the potential for fewer adverse events may be achieved through the precision targeting and the stable and flat delivery of the active ingredient when using the Diffusphere technology, versus the peaks and troughs seen with more traditional drug delivery methods. The precision of Eupraxia's Diffusphere technology platform has the potential to augment and transform existing FDA-approved (U.S. Food and Drug Administration) drugs to improve their safety, tolerability, efficacy and duration of effect. The potential uses in therapeutic areas may go beyond pain and inflammatory gastrointestinal disease, where Eupraxia currently is developing advanced treatments, to also be applicable in oncology, infectious disease and other critical disease areas.

Eupraxia's EP-104GI is currently in a phase 1b/2 trial, the Resolve trial, for the treatment of EoE. EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. This is a unique treatment approach for EoE. Eupraxia also completed a phase 2b clinical trial (Springboard) of EP-104IAR for the treatment of pain due to knee osteoarthritis. The trial met its primary end point and three of the four secondary end points. In addition, Eupraxia is developing a pipeline of later and earlier-stage long-acting formulations. Potential pipeline indications include candidates for other inflammatory joint indications and oncology, each designed to improve on the activity and tolerability of currently approved drugs.

We seek Safe Harbor.